CompletedPhase 3

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

140 participantsStarted 2016-05-25

Plain-language summary

This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 to 75 * Subjects had to have a confirmed clinical diagnosis of essential blepharospasm requiring treatment by injection Exclusion Criteria: * Subjects who underwent surgical operation * Subjects with Neuroleptic induced blepharospasm

What they're measuring

JRS (Jankovic Rating Scale) sum-score

Timeframe: From baseline at 4 week

Trial details

NCT IDNCT03216473

SponsorMedy-Tox

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-03-17

View on ClinicalTrials.gov More Essential Blepharospasm trials